Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06566547

GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma

Led by Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Updated on 2025-04-27

116

Participants Needed

1

Research Sites

152 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

All subjects will receive GR1803 injection until intolerable toxicity or investigator-assessed disease progression occurs (except in cases of disease progression due to discontinuation of the drug as a result of an adverse event) or until the subject has been administered the drug for 2 years or until the subject withdraws consent or until the investigator determines that the subject needs to be discontinued.

CONDITIONS

Official Title

GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • ECOG performance status score of 0 to 2
  • Age 18 years or older
  • Multiple myeloma measurable by central lab tests: serum monoclonal protein (M-protein) level at least 0.5 g/dL or urine M-protein level at least 200 mg/24 hours
  • For light chain multiple myeloma without measurable serum or urine disease: serum immunoglobulin free light chain (FLC) at least 10 mg/dL with abnormal kappa/lambda FLC ratio
Not Eligible

You will not qualify if you...

  • Prior treatment with any BCMA-targeted therapy
  • Known active central nervous system involvement or meningeal signs of multiple myeloma
  • Known allergies, hypersensitivity, or intolerance to teclistamab or its excipients
  • Diagnosis of plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome, or primary amyloid light-chain amyloidosis

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

he First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China, 310003

Actively Recruiting

Loading map...

Research Team

J

Jie Jin, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here